X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Elores
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
Xacduro (sulbactam & durlobactam), co-packaged for intravenous use, which act as beta-lactamase inhibitor, approved in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Xacduro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Xacduro (sulbactam for injection; durlobactam for injection), combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, approved for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Xacduro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
ETX2514 is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
ETX2514 or SUL-DUR is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
SUL-DUR is an IV, investigational drug that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV BLI, being developed for the treatment of infections caused by ABC, including carbapenem-resistant strains.
Lead Product(s): Sulbactam,Durlobactam,Imipenem
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Sulbactam-Durlobactam (SUL-DUR) is an IV, investigational drug that is combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, novel broad-spectrum IV BLI, developed for treatment of infections caused by ABC complex, including carbapenem-resistant strains.
Lead Product(s): Sulbactam,Durlobactam,Imipenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514sul
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Sulbactam (SUL-DUR) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Entasis brings to Innoviva an exciting portfolio that includes potentially first- and best-in-class medicines for the treatment of multidrug-resistant Gram-negative bacteria, including lead asset SUL-DUR.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 11, 2022
Details:
The primary efficacy endpoint, 28-day all-cause mortality (ACM) in carbapenem resistant Acinetobacter baumannii-calcoaceticus (CRABC) m-MITT cohort (n=125) was 19.0% (12/63) and 32.3% (20/62) for SUL-DUR versus colistin, respectively (difference -13.2% [95% CI: -30.0, 3.5]).
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
SUL-DUR (Sulbactam-durlobactam), is the first investigational drug to demonstrate efficacy in a 28-day all-cause mortality trial focused on carbapenem-resistant Acinetobacter, an “Urgent” threat as designated by the CDC.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
Entasis’ pathogen-targeted platform has a pipeline, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) & ETX0462 (targeting Gram-negative infections).
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 02, 2022
Details:
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients demonstrated statistical non-inferiority versus colistin.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
ATTACK is a Phase 3 registrational trial that will evaluate the safety and efficacy of SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter infections.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
Entasis plans to use the proceeds from the offering to support the continued development of its novel pipeline which includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Etx2514sul
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 03, 2021
Details:
First Chinese patient dosed in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter baumannii infections.
Lead Product(s): Durlobactam,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Entasis plans to use the proceeds from the offering to support the continued development of its novel pipeline of pathogen-targeted antibacterial product candidates SUL-DUR and zoliflodacin.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
